Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 30, 2025 • 3:11 PM ET

Date/Time Source News Release
04/17/2025 09:08 PM EDT Business Wire KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
04/17/2025 09:03 PM EDT Business Wire KILL Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)
04/17/2025 08:15 AM EDT Business Wire Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)
04/16/2025 08:15 AM EDT Business Wire Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
04/14/2025 08:15 AM EDT Business Wire Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
04/11/2025 08:15 AM EDT Business Wire Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
04/09/2025 08:15 AM EDT Business Wire Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
04/02/2025 08:17 AM EDT GlobeNewswire Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
04/02/2025 08:15 AM EDT Business Wire Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025
03/28/2025 08:15 AM EDT Business Wire Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
Page

Additional News

As of April 30, 2025 • 3:11 PM ET

Date/Time Source News Release
04/17/2025 10:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic's Dr. Charles Howe in May 2 Update on ADI-100(TM) Preclinical Study
04/16/2025 09:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
04/14/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Advances Autoimmune Therapy Following Positive Mayo Clinic Study on ADI-100
04/11/2025 08:45 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance and Previews Strategic Updates
04/09/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
04/09/2025 08:44 AM EDT SeekingAlpha Aditxt regains compliance with Nasdaq
04/02/2025 09:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
03/28/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
03/24/2025 09:45 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
03/18/2025 09:20 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Provides Update on Appili Therapeutics Acquisition and Federal Funding Applications
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.